Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy
| Autor: | Felipe F. Casanueva, Mónica Marazuela, Paz de Miguel-Novoa, Manel Puig-Domingo, Ignacio Bernabeu, Cristina Álvarez-Escolá, Alejandra Duran-Hervada, Nuria Garcia de la Torre, Irene Halperin, Tomás Lucas, Rafael Manzanares, Manuel Luque-Ramírez |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Endocrinology Diabetes and Metabolism medicine.medical_treatment Drug Resistance Context (language use) Diabetes Complications Young Adult Endocrinology Internal medicine Acromegaly Diabetes Mellitus medicine Humans Insulin-Like Growth Factor I Young adult Adverse effect Aged Response rate (survey) Sex Characteristics Human Growth Hormone business.industry Receptors Somatotropin General Medicine Middle Aged medicine.disease Long-Term Care Recombinant Proteins Radiation therapy Somatostatin Pegvisomant Female business medicine.drug |
| Zdroj: | European Journal of Endocrinology. 160:535-542 |
| ISSN: | 1479-683X 0804-4643 |
| DOI: | 10.1530/eje-08-0705 |
| Popis: | ContextPegvisomant is an effective treatment for somatostatin analogue-resistant acromegaly, but the determinants defining the response to this treatment are largely unknown.ObjectiveTo investigate the efficacy of pegvisomant treatment in resistant acromegalic patients (e.g. serum IGF1 at least 1.25×upper normal limit) in a clinical setting and the factors conditioning this response.Design and settingA retrospective cross-sectional study performed in six Spanish University hospitals from 2004 to 2007.PatientsForty-four acromegalic patients (61.4% female, mean age: 49±14), 95% of whom had undergone pituitary surgery and 61% having received pituitary radiotherapy. The mean follow-up was 22.7±11.2 months.Main outcome measuresIGF1 levels reflected treatment efficacy, and the influence of gender, age, weight, previous radiotherapy and duration of treatment was assessed.ResultsIGF1 normalisation was achieved in 84% of the patients. Male gender (PPr=0.364, PPPConclusionsLong-term pegvisomant is a very effective therapy in resistant acromegaly. Male gender and prior radiotherapy influence the therapeutic response rate. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|